The Interventional Pharmacoeconomic Toolbox Panel Discussion

First International Summit on Interventional Pharmacoeconomics

Peter Clark, MA, MD, FRCP: A Payer Perspective

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

David A. Hyman, MD, JD, on Inclusive Shared Savings

Issues in Oncology

The ASCO Post Staff

Leonard B. Saltz, MD, on Interventional Pharmacoeconomics: A Pathway to Better Cancer Care

Leonard B. Saltz, MD, of Memorial Sloan Kettering Cancer Center, discusses interventional pharmacoeconomics as an important tool that can offer patients with cancer more efficacious and cost-effective care. Pharmacoeconomics may help reduce the high costs of cancer therapy, with evidence-based reductions in doses that maintain effective treatment.

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Nov

Today In Oncology

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Related Videos

Peter Clark, MA, MD, FRCP: A Payer Perspective

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

David A. Hyman, MD, JD, on Inclusive Shared Savings

Leonard B. Saltz, MD, on Interventional Pharmacoeconomics: A Pathway to Better Cancer Care

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

FDA Approves Durvalumab With FLOT for Resectable Gastric-GEJ Adenocarcinoma

AI Simplifies Patients Comprehension of CT Reports But Are Errors Possible

External Validation Confirms Ability of AI Model to Stratify Recurrence Risk in Early-Stage Lung Cancer

No Overall Survival Benefit for Lenvatinib in LEAP-014 Trial of Esophageal Cancer

ASTRO Publishes First Clinical Guideline on Radiation Therapy for Gastric Cancer